Current Oncology, Free Full-Text
Por um escritor misterioso
Descrição
Background: Information on immune responses in cancer patients following mRNA COVID-19 vaccines is still insufficient, but generally, patients had impaired serological responses, especially those with hematological malignancies. We evaluated serological response to COVID-19 mRNA vaccine in cancer patients receiving chemotherapy compared with healthy controls. Methods: In total, 195 cancer patients and 400 randomly selected controls who had been administered a Pfizer-BioNTech or Moderna COVID-19 vaccines in two doses were compared. The threshold of positivity was 4.33 BAU/mL. Patients were receiving anticancer treatment after the first and second dose of the vaccines. Results: a TOTAL OF 169 patients (87%) had solid tumors and 26 hemolymphopoietic diseases. Seropositivity rate was lower in patients than controls (91% vs. 96%), with an age/gender-adjusted rate ratio (RR) of 0.95 (95% CL = 0.89–1.02). Positivity was found in 97% of solid cancers and in 50% of hemolymphopoietic tumors. Both advanced and adjuvant therapy seemed to slightly reduce seropositivity rates in patients when compared to controls (RR = 0.97, 95% CL = 0.89–1.06; RR = 0.94, 95% CL = 0.87–1.01). Conclusions: the response to vaccination is similar in patients affected by solid tumors to controls. On the contrary, hemolymphopietic patients show a much lower response than controls.
Current Oncology An Open Access Journal from MDPI
Home Page: Lung Cancer
Journal of Current Oncology: Sage Journals
Free Oncology CE and CME for Healthcare Professionals
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study - The Lancet Oncology
Malignant: How Bad Policy and Bad by Prasad, Vinayak K.
Breast cancer - Wikipedia
Lisa Grech on X: We #validated a tool to understand #COVID-19 #vaccine #vulnerability and #disease #vulnerability in #cancer, #diabetes, #multiplesclerosis) Now published in: #BehavioralMedicine @profevasegelov @alastair_kwok Access for #free at this
Current Oncology An Open Access Journal from MDPI
Noninvasive detection of any-stage cancer using free glycosaminoglycans
PDF) Management of locally advanced breast cancer: Evolution and current practice
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Journal of the American College of Surgeons
Current Oncology An Open Access Journal from MDPI
